NCT03713294View on ClinicalTrials.gov

Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple Myeloma

PHASE2CompletedINTERVENTIONAL

Enrollment

37

Participants

Timeline

Start Date

January 14, 2019

Primary Completion Date

February 20, 2024

Study Completion Date

November 14, 2024

Conditions

Refractory Plasma Cell Myeloma

Interventions

DRUG

Dexamethasone

Given IV and PO

BIOLOGICAL

Elotuzumab

Given IV

DRUG

Pomalidomide

Given PO

Trial Locations (1)

32224-9980

Mayo Clinic in Florida, Jacksonville

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Mayo Clinic

OTHER